Glioblastoma multiforme laboratory tests

Revision as of 16:22, 14 March 2019 by Marjan Khan (talk | contribs)
Jump to navigation Jump to search

Glioblastoma multiforme Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glioblastoma multiforme from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glioblastoma multiforme laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glioblastoma multiforme laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glioblastoma multiforme laboratory tests

CDC on Glioblastoma multiforme laboratory tests

Glioblastoma multiforme laboratory tests in the news

Blogs on Glioblastoma multiforme laboratory tests

Directions to Hospitals Treating Glioblastoma multiforme

Risk calculators and risk factors for Glioblastoma multiforme laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

Biomarkers are potentially a non-invasive and universal diagnostic tool that focuses on molecular markers over the phenotypic differences described through biopsy. GBM microvesicles may prove to be useful in this respect. Microvesicles are plasma membrane-derived membrane-enclosed particles that are released from cells through membrane fission and can carry mRNA, miRNA, and proteins from the parent cell. When these microvesicles are GBM derived, the tumor-specific contents can adjust the nearby microenvironment to be more hospitable to tumor growth. Patient serum may provide prognostic information as it has also been used to detect a small non-coding RNA, RNU6-1, which is an independent predictor of GBM (Manterola et al, 2014). Clearly, the serum composition of GBM patients should be further studied as it may non-invasively provide highly valuable prognostic information for treating GBM beyond the current paradigms.

Laboratory Tests

  • Biomarkers are potentially a non-invasive and diagnostic tool that focuses on molecular markers over the phenotypic differences.
  • Microvesicles are plasma membrane-derived membrane-enclosed particles that are released from cells and can carry mRNA.
  • When these microvesicles are GBM derived the tumor-specific contents can adjust the nearby microenvironment to be more hospitable to tumor growth.
  • Microfluidic chips can be used to detect microvesicles in the bloodstream.
  • Microfludic have been shown to detect a significant dose-dependent post-temozolomide (TMZ) treatment decline in microvesicle populations.
  • Microvesicles can model the profile of the tumor cell including changes in IDH-1, EGFR, and EGFRvIII.
  • The information provided by microvesicle detection may provide a quick and non-invasive biomarker of GBM status using patient blood samples.
  • Many peptides have been found to change in CSF samples between normal and GBM patients.
  • Increase in albumin, osteopontin, and others might suggest that peptide levels in the CSF reflect changes in the nervous system environment that could be used to determine the status of a GBM tumor.
  • Routine blood sampling after GBM resection may allow early detection of recurrence, thus reducing the time from tumor regrowth to second-line treatment.

References


Template:WikiDoc Sources